Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer

BACKGROUND: Pembrolizumab is recommended as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) and a Programmed cell death ligand-1 (PD-L1) tumor proportion score (TPS) of ≥50% without driver mutations. However, the safety and efficacy were not investigated among patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Takeshi, Fujitaka, Kazunori, Ishikawa, Nobuhisa, Nakano, Kikuo, Yamasaki, Masahiro, Kitaguchi, Souichi, Masuda, Ken, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Horimasu, Yasushi, Kawase, Shigeo, Miyamoto, Shintaro, Nakashima, Taku, Iwamoto, Hiroshi, Shiota, Naoki, Senoo, Tadashi, Awaya, Yoshikazu, Kondo, Tomohiro, Yoshida, Takashi, Hamada, Hironobu, Murakami, Isao, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Study Protocal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139059/
https://www.ncbi.nlm.nih.gov/pubmed/32274176
http://dx.doi.org/10.21037/jtd.2019.12.46

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139059/
https://www.ncbi.nlm.nih.gov/pubmed/32274176
http://dx.doi.org/10.21037/jtd.2019.12.46

Ejemplares similares